Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19231212 | MUSCLE TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO TREAT DUCHENNE MUSCULAR DYSTROPHY | June 2025 | September 2025 | Allow | 4 | 1 | 0 | No | No |
| 19211660 | COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF DELIVERING OLIGONUCLEOTIDE TO A SUBJECT | May 2025 | August 2025 | Allow | 3 | 0 | 1 | Yes | No |
| 19189163 | COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF DELIVERING AN OLIGONUCLEOTIDE TO A SUBJECT | April 2025 | September 2025 | Allow | 5 | 1 | 0 | No | No |
| 19094954 | RNAi Agents for Inhibiting Expression of Microtubule Associated Protein Tau (MAPT), Compositions Thereof, and Methods of Use | March 2025 | October 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 19085184 | ANTI-HUMAN INTERLEUKIN 36 RECEPTOR MONOCLONAL ANTIBODY AND METHODS OF USE THEREOF TO TREAT DISEASE | March 2025 | October 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 19065946 | MUSCLE TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO INDUCE EXON SKIPPING OF EXON 44 OF DYSTROPHIN IN A SUBJECT | February 2025 | May 2025 | Allow | 2 | 0 | 1 | Yes | No |
| 19066035 | Complexes Comprising An Anti-transferrin Receptor Antibody Linked to An Oligonucleotide And Method Of Delivering Oligonucleotide To A Subject | February 2025 | June 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19058780 | ANTIBODIES THAT BIND THE SPIKE PROTEIN OF SARS-COV-2 | February 2025 | September 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 19046824 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF USE THEREOF TO INDUCE EXON SKIPPING | February 2025 | May 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 18940209 | METHOD OF USING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY TO DELIVER AN OLIGONUCLEOTIDE TO A SUBJECT HAVING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | November 2024 | March 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18939894 | COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHOD OF DELIVERING OLIGONUCLEOTIDE TO A SUBJECT | November 2024 | April 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18927497 | POLYPEPTIDE COMPRISING A SINGLE-DOMAIN ANTIBODY VARIABLE REGION THAT BINDS DELTA-LIKE LIGAND 3 (DLL3) AND METHOD OF USE THEREOF TO MAKE A RADIONUCLIDE COMPLEX | October 2024 | April 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18920375 | ANTI-CD19 ANTIBODY DRUG CONJUGATES | October 2024 | July 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18896799 | METHOD OF TREATING AN INTERLEUKIN-11-ASSOCIATED OR -MEDIATED FIBROTIC DISEASE OR CONDITION BY ADMINISTERING AN ANTI-INTERLEUKIN-11 RECEPTOR SUBUNIT ALPHA (IL-11RA) ANTIBODY | September 2024 | March 2025 | Allow | 6 | 1 | 1 | No | No |
| 18844737 | ANTIBODIES THAT INHIBIT ERYTHROPOIETIN RECEPTOR ACTIVATION AND METHODS OF USE THEREOF TO TREAT CANCER | September 2024 | January 2026 | Allow | 16 | 2 | 1 | Yes | No |
| 18844732 | METHOD OF TREATING CANCER BY ADMINISTERING AN INHIBITOR OF ERYTHROPOIETIN RECEPTOR ACTIVITY COMPRISING EITHER ERYTHROPOIETIN RECEPTOR OR ERYTHROPOIETIN PROTEIN | September 2024 | August 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18806325 | BISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND ENCODING POLYNUCLEOTIDES, VECTORS AND CELLS THEREOF | August 2024 | July 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18759724 | COMPOSITIONS COMPRISING PLN-TARGETING ANTI-TRANSFERRIN RECEPTOR ANTIBODY-POLYNUCLEOTIDES AND METHODS OF USE THEREOF TO TREAT CARDIOMYOPATHY | June 2024 | June 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18753994 | METHOD OF MONITORING ANTI-TNF THERAPY IN A SUBJECT SUFFERING FROM RHEUMATOID ARTHRITIS BASED IN PART ON A TRAINED MACHINE LEARNING CLASSIFIER | June 2024 | September 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18656654 | COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE | May 2024 | August 2024 | Allow | 4 | 1 | 1 | No | No |
| 18656672 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE | May 2024 | August 2024 | Allow | 4 | 1 | 1 | Yes | No |
| 18651734 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHODS OF USE THEREOF TO TARGET DYSTROPHIN AND TO TREAT DUCHENNE MUSCULAR DYSTROPHY | May 2024 | January 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18629444 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE WHICH BINDS CLAUDIN-6 and CLAUDIN-9 | April 2024 | September 2024 | Allow | 6 | 1 | 1 | No | No |
| 18593157 | ANTI-HUMAN THYMIC STROMAL LYMPHOPOIETIN (TSLP) MONOCLONAL ANTIBODY AND USE THEREOF TO TREAT DISEASE | March 2024 | June 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18590853 | ANTI-INTERLEUKIN-11 RECEPTOR SUBUNIT ALPHA (IL-11RA) ANTIBODIES | February 2024 | September 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18443970 | MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO THIOREDOXIN 1 AND METHODS OF USE THEREOF FOR BREAST CANCER DIAGNOSIS | February 2024 | October 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18443945 | MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO THIOREDOXIN 1 AND METHODS OF USE THEREOF FOR BREAST CANCER DIAGNOSIS | February 2024 | October 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18442906 | ANTIBODIES AND ASSAYS FOR DETECTION OF FOLATE RECEPTOR 1 | February 2024 | March 2026 | Abandon | 25 | 1 | 1 | No | No |
| 18437617 | CONNEXIN 43 (Cx43) HEMICHANNEL-BINDING ANTIBODIES | February 2024 | August 2025 | Allow | 18 | 1 | 1 | No | No |
| 18431764 | NUCLEIC ACIDS, VECTORS, AND CELLS THAT ENCODE ANTIBODIES AND OTHER PROTEINS THAT BIND FOLATE RECEPTOR ALPHA | February 2024 | January 2025 | Allow | 12 | 1 | 1 | No | No |
| 18400943 | METHODS FOR MAKING RADIOLABELED ANTI-MET BINDING PROTEINS | December 2023 | December 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18542929 | POLYNUCLEOTIDES ENCODING ANTI-GLUCAGON-LIKE PEPTIDE 1 RECEPTOR (GLP1R) ANTAGONIST ANTIBODIES | December 2023 | June 2025 | Allow | 17 | 1 | 1 | No | No |
| 18542451 | METHODS AND USES OF PROTEIN DISULFIDE ISOMERASE INHIBITORY COMPOUNDS | December 2023 | August 2025 | Abandon | 20 | 0 | 1 | Yes | No |
| 18538748 | COMPOSITION COMPRISING ANTI-GLIADIN ANTIBODIES AND METHOD OF USE THEREOF TO DETECT GLIADIN IN A SAMPLE | December 2023 | August 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18529915 | BISPECIFIC CHIMERIC ANTIGEN RECEPTOR THAT BINDS CD19 AND CD20, ENCODING NUCLEIC ACID MOLECULES THEREOF AND METHODS OF USE THEREOF TO TREAT CANCER | December 2023 | November 2025 | Allow | 23 | 1 | 1 | No | No |
| 18528957 | METHOD OF TREATING AN OCULAR CONDITION BY ADMINISTERING MULTISPECIFIC ANTIBODIES THAT ACTIVATES TIE2 AND BINDS A RECEPTOR TYROSINE KINASE AGONIST | December 2023 | April 2025 | Allow | 17 | 0 | 1 | No | No |
| 18523048 | METHOD OF REDUCING SERUM AMYLOID A (SAA) PROTEIN LEVELS IN A PATIENT BY ADMINISTERING AN INTERLEUKIN-33 (IL-33) ANTIBODY | November 2023 | December 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18384230 | HUMANIZED ANTIBODIES RECOGNIZING SORTILIN | October 2023 | May 2024 | Allow | 7 | 1 | 0 | No | No |
| 18383121 | LYOPHILIZED POWDER CONFIGURED FOR RECONSTITUTION AS A LIQUID PHARMACEUTICAL FORMULATION WITH REDUCED VISCOSITY AND METHOD OF PREPARING THEREOF | October 2023 | April 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18481578 | BINDING AGENTS THAT BIND OX40 (CD134) AND METHOD OF USE THEREOF TO TREAT DISEASE | October 2023 | May 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18475582 | ANTI-HLA-A2 ANTIBODIES AND USES THEREOF | September 2023 | January 2026 | Abandon | 28 | 1 | 1 | No | No |
| 18474096 | METHODS OF TREATING CANCER WITH NONFUCOSYLATED ANTI-CD70 ANTIBODIES | September 2023 | August 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18468580 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE AND METHODS OF DELIVERING OLIGONUCLEOTIDE TO A SUBJECT | September 2023 | April 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18467851 | MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE | September 2023 | April 2024 | Allow | 7 | 1 | 1 | No | No |
| 18463037 | COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES TO HUMAN ADAMTS5 AND NERVE GROWTH FACTOR | September 2023 | April 2024 | Allow | 7 | 2 | 1 | Yes | No |
| 18456323 | ANTIBODIES SPECIFIC FOR HUMAN COMPLEMENT C5A RECEPTOR (C5AR) | August 2023 | April 2024 | Allow | 7 | 1 | 1 | No | No |
| 18454391 | METHODS OF DIAGNOSING CERVICAL CANCER BASED ON ALTERED POLYPEPTIDE EXPRESSION AND TREATMENT THEREOF | August 2023 | July 2025 | Allow | 23 | 1 | 1 | No | No |
| 18450222 | METHODS OF TREATING A SUBJECT SUFFERING FROM RHEUMATOID ARTHRITIS WITH ANTI-TNF THERAPY BASED IN PART ON A TRAINED MACHINE LEARNING CLASSIFIER | August 2023 | April 2024 | Allow | 8 | 1 | 1 | Yes | No |
| 18365536 | METHODS FOR TREATING DIGITALLY-IDENTIFIED IL-4/IL-13 RELATED DISORDERS | August 2023 | December 2024 | Abandon | 16 | 2 | 1 | Yes | No |
| 18365505 | METHOD OF TREATING AN EYE-RELATED DISORDER BY ADMINISTERING AN ANTI-INTERLEUKIN-4 RECEPTOR ALPHA (ANTI-IL-4RA) ANTIBODY | August 2023 | April 2024 | Allow | 8 | 2 | 1 | Yes | No |
| 18359437 | METHOD OF CHARACTERIZING A TUMOR BASED ON AN IMMUNE GENE EXPRESSION SIGNATURE IN REGULATORY T CELL (TREG)-ENRICHED TUMOR SAMPLES | July 2023 | July 2025 | Allow | 24 | 2 | 1 | No | No |
| 18347626 | NUCLEIC ACIDS ENCODING FCRN-BINDING ANTIBODIES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE THEREOF TO MAKE ANTIBODIES | July 2023 | June 2025 | Allow | 24 | 1 | 0 | No | No |
| 18344311 | ANTIBODIES WITH IMPROVED STABILITY TO INTESTINAL DIGESTION, POLYNUCLEOTIDES THEREOF AND METHODS OF USE THEREOF TO TREAT DISEASE | June 2023 | May 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18342572 | GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE THEREOF | June 2023 | October 2025 | Abandon | 28 | 1 | 1 | Yes | No |
| 18212542 | METHODS OF TREATING PATIENTS AFFLICTED WITH IRRITABLE BOWEL SYNDROME, INFLAMMATORY BOWEL DISEASE OR CHRONIC GASTROINTESTINAL FUNCTIONAL DISORDERS BASED ON ASSESSMENT OF INTESTINAL BARRIER FUNCTION | June 2023 | April 2025 | Allow | 21 | 1 | 1 | No | No |
| 18337930 | METHODS FOR TREATING DIGITALLY-IDENTIFIED IL-4/IL-13 RELATED DISORDERS BY ADMINISTERING AN ANTI-IL4R-ALPHA ANTIBODY | June 2023 | August 2025 | Abandon | 26 | 1 | 0 | Yes | No |
| 18337901 | MODULATION OF IFI16 AND STING ACTIVITY | June 2023 | May 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18335636 | ANTI-CD19 ANTIBODY DRUG CONJUGATES | June 2023 | June 2024 | Allow | 12 | 0 | 1 | Yes | No |
| 18334574 | ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES | June 2023 | September 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18329069 | METHODS OF TREATING PNEUMONIA OR RESPIRATORY FAILURE ASSOCIATED WITH COVID-19 BY ADMINISTERING AN ANTI-LIGHT ANTIBODY | June 2023 | February 2025 | Allow | 20 | 1 | 0 | No | No |
| 18323543 | METHOD OF INCREASING PROTEIN PRODUCTION IN A CHINESE HAMSTER OVARY PERFUSION CELL CULTURE | May 2023 | April 2025 | Allow | 23 | 1 | 1 | Yes | No |
| 18316210 | TREATMENT OF CANCER USING INHIBITORS OF TGF-BETA AND PD-1 | May 2023 | July 2025 | Abandon | 26 | 1 | 0 | Yes | No |
| 18314117 | ANTIBODIES THAT BIND TO C-TYPE LECTIN DOMAIN FAMILY 2 MEMBER D (CLEC2D) | May 2023 | July 2025 | Allow | 26 | 1 | 1 | No | No |
| 18313858 | ANTI-CD96 ANTIBODIES AND METHODS OF USE THEREOF | May 2023 | September 2025 | Abandon | 28 | 1 | 1 | No | No |
| 18309450 | METHOD OF REDUCING OR TREATING FIBROSIS BY ADMINISTERING AN INTERLEUKIN-2/TGF-BETA RECEPTOR FUSION POLYPEPTIDE | April 2023 | February 2025 | Allow | 21 | 1 | 1 | No | No |
| 18033600 | TYPE-II VNAR POLYPEPTIDES WHICH BIND HUMAN TFR-1, ENCODING NUCLEIC ACIDS THEREOF AND METHOD OF USE THEREOF | April 2023 | August 2024 | Allow | 16 | 1 | 1 | No | No |
| 18305235 | METHOD OF TREATING TYPE 1 INTERFERON (IFN)-MEDIATED DISEASE USING A SUBCUTANEOUS DOSING REGIMEN COMPRISING ANIFROLUMAB | April 2023 | May 2024 | Allow | 13 | 2 | 2 | No | No |
| 18304883 | METHOD OF ADMINISTERING LAPATINIB TO A CANINE TO TREAT BLADDER CANCER HARBORING A BRAF MUTATION | April 2023 | April 2024 | Allow | 11 | 1 | 1 | Yes | No |
| 18029540 | METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY ADMINISTERING AN ANTI-EPHRIN TYPE-A RECEPTOR 4 (EPHA4) ANTIBODY | March 2023 | January 2026 | Allow | 34 | 1 | 0 | No | No |
| 18184741 | MUSCLE-TARGETING COMPLEX COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE | March 2023 | July 2023 | Allow | 5 | 2 | 0 | No | No |
| 18184905 | METHODS OF PRODUCING MUSCLE-TARGETING COMPLEXES COMPRISING AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY LINKED TO AN OLIGONUCLEOTIDE | March 2023 | August 2023 | Allow | 5 | 1 | 1 | No | No |
| 18182166 | NUCLEIC ACIDS ENCODING, AND METHODS OF PRODUCING, ANTIBODIES THAT BIND HUMAN CHEMOKINE (C-C MOTIF) RECEPTOR 8 (CCR8) | March 2023 | January 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18181450 | ANTI-C-MET ANTIBODY DRUG CONJUGATES | March 2023 | July 2024 | Abandon | 16 | 0 | 0 | No | No |
| 18168519 | METHODS OF ENRICHING OR AMPLIFYING NUCLEIC ACIDS IN A SAMPLE FROM A PATIENT WITH INFLAMMATORY BOWEL DISEASE | February 2023 | April 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 18164206 | ANTIBODIES AGAINST CARCINOEMBRYONIC ANTIGENS | February 2023 | July 2023 | Allow | 6 | 1 | 1 | Yes | No |
| 18019001 | INTERFERON-GAMMA R2 (IFNGR2) BINDING MOLECULES COMPRISING SINGLE-DOMAIN ANTIBODIES AND METHOD OF USE THEREOF TO TREAT AUTOIMMUNE AND INFLAMMATORY DISEASES | January 2023 | February 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18162447 | BISPECIFIC CHIMERIC ANTIGEN RECEPTORS, ENCODING POLYNUCLEOTIDES AND USE OF RECEPTORS THEREOF TO TREAT CANCER | January 2023 | May 2024 | Allow | 15 | 2 | 1 | No | No |
| 18158852 | RECOMBINANT VIRUS VECTOR (RVV) FOR INHIBITING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVITY AND METHOD OF MAKING AN AGENT/TARGET CELL COMPLEX TO INCREASE CETUXIMAB-LIKE PROTEIN (CLP) PRODUCITON | January 2023 | April 2025 | Allow | 27 | 3 | 1 | Yes | No |
| 18017593 | IL28RA BINDING MOLECULES COMPRISING A SINGLE-DOMAIN ANTIBODY | January 2023 | July 2024 | Allow | 17 | 2 | 1 | No | No |
| 18006169 | ANTIBODIES THAT BIND HUMAN AND MOUSE INSL5 AND ENCODING NUCLEIC ACIDS THEREOF | January 2023 | January 2026 | Allow | 36 | 0 | 0 | No | No |
| 18005979 | MONOCLONAL ANTIBODIES AGAINST HENIPAVIRUS GLYCOPROTEIN G AND ENCODING NUCLEIC ACIDS THEREOF | January 2023 | November 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 18095753 | METHOD OF TREATING DISEASES OF THE KIDNEY AND URINARY TRACT BY ADMINISTERING A PEPTIDE-LINKED THERAPEUTIC AGENT | January 2023 | November 2024 | Allow | 22 | 0 | 1 | Yes | No |
| 18091361 | METHODS FOR TREATING CANCER USING SOLUBLE FORMS OF PSGL-1 AND FUSION MOLECULES THEREOF | December 2022 | November 2024 | Allow | 23 | 2 | 1 | Yes | No |
| 18146773 | METHODS OF TREATING CANCER WITH INTERFERON WHEREIN THE CANCER CELLS ARE HLA NEGATIVE OR HAVE REDUCED HLA EXPRESSION | December 2022 | August 2025 | Abandon | 31 | 2 | 0 | No | No |
| 18065371 | METHODS OF TREATING CANCER BY ADMINISTERING AN ANTIBODY-DRUG CONJUGATE TARGETING HUMAN CLAUDIN 18.2 | December 2022 | February 2025 | Allow | 26 | 1 | 1 | No | No |
| 18079307 | METHOD FOR PRODUCING BISPECIFIC ANTIBODIES COMPRISING A Y436A FC-REGION MUTATION FOR IMPROVED PROTEIN A-BINDING | December 2022 | May 2025 | Allow | 29 | 1 | 1 | No | No |
| 18062473 | HUMAN ANTIBODIES AGAINST TISSUE FACTOR AND METHODS OF USE THEREOF | December 2022 | August 2025 | Abandon | 32 | 1 | 1 | No | No |
| 18062265 | Compositions and Methods for Treating Cancer | December 2022 | February 2025 | Abandon | 27 | 0 | 1 | No | No |
| 17926295 | ANTIBODIES WHICH BIND HUMAN ENDOTHELIN RECEPTOR A (ETAR) | November 2022 | December 2025 | Allow | 37 | 1 | 0 | No | No |
| 17926018 | METHODS OF TREATING RHEUMATOID ARTHRITIS IN A SUBJECT INEFFECTIVELY TREATED WITH A JANUS KINASE INHIBITOR (JAKI) COMPRISING ADMINISTERING AN ANTIBODY AGAINST A HUMAN INTERLEUKIN-6 RECEPTOR | November 2022 | December 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 18056029 | ENGINEERED EXTRACELLULAR VESICLES COMPRISING FUSION PROTEINS | November 2022 | March 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 18055340 | TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR IGM ANTIBODIES AND USES THEREOF | November 2022 | February 2025 | Abandon | 27 | 0 | 1 | No | No |
| 17974949 | ANTI-HLA-DQ2.5 ANTIBODY AND METHOD OF USE THEREOF TO TREAT CELIAC DISEASE | October 2022 | March 2025 | Allow | 28 | 1 | 1 | No | No |
| 18050234 | TRANSFERRIN RECEPTOR (TFR)-SELECTIVE BINDING PEPTIDES CAPABLE OF CROSSING THE BLOOD BRAIN BARRIER, ENCODING NUCLEIC ACIDS THEREOF AND METHODS OF USE THEREOF | October 2022 | January 2025 | Allow | 27 | 1 | 1 | No | No |
| 18045592 | HUMAN ANTIBODIES TO THE HUMAN GLUCAGON RECEPTOR (HGCGR) AND METHODS OF USE THEREOF TO LOWER BLOOD GLUCOSE OR KETONE LEVELS | October 2022 | November 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17938674 | ANTI-INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R) ANTIBODIES AND METHOD OF USE THEREOF TO TREAT THYROID-ASSOCIATED OPTHAMOLOGY | October 2022 | February 2026 | Allow | 40 | 1 | 1 | Yes | No |
| 17936483 | METHODS OF USING MUSCLE TARGETING COMPLEXES TO DELIVER AN OLIGONUCLEOTIDE TO A SUBJECT HAVING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY OR A DISEASE ASSOCIATED WITH MUSCLE WEAKNESS | September 2022 | February 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 17934441 | METHOD OF ASSESSING THE EFFICACY OF A TEST AGENT FOR MODULATING PROGRAMMED DEATH 1 (PD-1) SIGNALING BY USING ANTI-PHOSPHOTYROSINYLATED PD-1 MONOCLONAL ANTIBODIES | September 2022 | January 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 17941741 | ANTI-HUMAN NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) ANTIBODIES | September 2022 | August 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17930545 | METHOD OF DEPLETING TARGET ANTIGEN-SPECIFIC ANTIBODY FROM A PATIENT BY ADMINISTERING A FUSION PROTEIN (SELDEG) FOR SELECTIVELY DEPLETING ANTIGEN-SPECIFIC ANTIBODIES | September 2022 | April 2025 | Allow | 32 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LANDSMAN, ROBERT S.
With a 22.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 29.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LANDSMAN, ROBERT S works in Art Unit 1647 and has examined 1,514 patent applications in our dataset. With an allowance rate of 69.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 26 months.
Examiner LANDSMAN, ROBERT S's allowance rate of 69.2% places them in the 31% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by LANDSMAN, ROBERT S receive 1.50 office actions before reaching final disposition. This places the examiner in the 26% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by LANDSMAN, ROBERT S is 26 months. This places the examiner in the 75% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +24.8% benefit to allowance rate for applications examined by LANDSMAN, ROBERT S. This interview benefit is in the 71% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 37.7% of applications are subsequently allowed. This success rate is in the 86% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 76.9% of cases where such amendments are filed. This entry rate is in the 95% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 80.4% of appeals filed. This is in the 74% percentile among all examiners. Of these withdrawals, 81.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 54.4% are granted (fully or in part). This grant rate is in the 55% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 11.0% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.5% of allowed cases (in the 82% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.